Tempus AI, Inc. (NASDAQ: TEM) shares have surged following the announcement that the company has surpassed 500 research papers. As of the latest check during the morning session, TEM stock experienced a 6.19% increase, reaching $39.82.
A Leader in Artificial Intelligence and Precision Medicine
Tempus (TEM), being a prominent entity in artificial intelligence and precision medicine, has achieved a significant research milestone, surpassing 500 published research papers. Over the past eight years, Tempus has dedicated substantial resources to scientific research to validate its diagnostic products.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Collaborating with biopharmaceutical companies and academic institutions, Tempus has published research bolstered by its extensive multimodal data library. This accomplishment encompasses 143 peer-reviewed articles, of which 106 are authored by Tempus, 291 poster presentations derived from clinical and research data presented at major scientific conferences, and 31 oral presentations at scientific meetings.
Commitment to Scientific Rigor and Clinical Validation
Tempus has consistently prioritized scientific rigor in its offerings, producing high-quality research over the past eight years. The company believes its solutions can significantly advance clinical care for patients, and the extensive breadth and depth of its research underscore this conviction.
In addition to clinically validating each of its tests, including algorithmic diagnostics like HRD and TO, Tempus has published pivotal research on the clinical utility of its comprehensive portfolio of molecular profiling tests.
Presence at Top Oncology Conferences
Tempus has established a substantial presence at leading oncology conferences worldwide, such as the ASCO Annual Meeting and the American Association for Cancer Research (AACR) Annual Meeting. The company has presented nearly 280 authored presentations, highlighting how its genomic sequencing tests and multimodal database are advancing both patient care and the development of next-generation cancer treatments.
Sharing research discoveries with the medical community is essential for institutions such as Tempus, as they are dedicated to promoting scientific research. Data is essential for researchers to further their findings, and fighting diseases like cancer will need the combined power of the entire ecosystem.
